A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis - Trial NCT05089409
Access comprehensive clinical trial information for NCT05089409 through Pure Global AI's free database. This Phase 1 trial is sponsored by AmtixBio Co., Ltd. and is currently Not yet recruiting. The study focuses on Onychomycosis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AmtixBio Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 08, 2021
Apr 30, 2023
Primary Outcome
To assess the safety and tolerability of multiple ascending doses (MAD) of ATB1651 in participants with mild to moderate onychomycosis through the percentage and severity of adverse events including pain, erythema and local irritation
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in
 participants with mild to moderate onychomycosis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05089409
Non-Device Trial